GCG and metabolic dysfunction-associated steatohepatitis: The combination of both GLP-1 agonist and SGLT-2-inhibitor already showed remarkable improvements of the metabolic condition in the treatment of T2DM [8] and therefore seems to be a promising therapy concept for NASH and diabetes.